According to the latest report by IMARC Group “Erythropoietin Drugs Market Report: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026″, The global erythropoietin drugs market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 6% during 2021-2026.
Erythropoietin (EPO) represents a hormone secreted by kidneys, which stimulates red blood cell (RBC) production. Its deficiency may cause low hemoglobin levels and various other medical conditions. EPO drugs or EPO stimulating agents (ESAs) are produced synthetically by applying recombinant Deoxyribonucleic acid (DNA) technology. They are typically administered through the intramuscular route and absorbed by the bloodstream to prompt RBC production. EPO drugs are commonly given to patients undergoing chemotherapy, chronic renal failure, antiviral drug therapy, etc.
Request for a free sample copy of this report: https://www.imarcgroup.com/erythropoietin-drugs-market/requestsample
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
The increasing number of individuals with anemia due to cancer, chronic kidney disease (CKD), prematurity, etc., is primarily driving the demand for EPO drugs. Moreover, these drugs are also used for treating zidovudine among patients with human immunodeficiency virus (HIV) infection. Additionally, with the growing geriatric population across the globe, there is an elevating requirement for surgical interventions, which is encouraging product use for minimizing allogeneic blood transfusions after surgical procedures. Furthermore, the rising utilization of ESAs as a novel therapeutic agent for research purposes is also expanding their applications in treating numerous conditions, such as spinal cord injury (SCI), diabetes, acute kidney injury (AKI), etc. Apart from this, the increasing popularity of minimally invasive (MI) procedures is anticipated to further bolster the EPO drugs market over the forecasted period.
Breakup by Drug Class:
Breakup by Product Type:
Breakup by Application:
- Kidney Disorder
Breakup by End User:
- Specialty Clinics
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Competitive Landscape with Key Player:
- Amgen Inc.
- Biocon Limited
- Dr. Reddy’s Laboratories Ltd.
- F. Hoffmann-La Roche AG
- Intas Pharmaceuticals Ltd.
- Johnson & Johnson
- LG Chem Ltd.
- Pfizer Inc.
- Sun Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Ltd.
Ask Analyst for Customization and Browse full report with TOC & List of Figure: https://www.imarcgroup.com/erythropoietin-drugs-market
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
If you want latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800